Ganirelix Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Ganirelix Formulation

Manufacturer or supplier's details

Company name of supplier : Organon & Co.

Address : Avenida 16 de Septiembre No. 301

Xaltocan - Xochimilco Mexico 16090

Telephone : +52 55 57284444 Emergency telephone : 1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Reproductive toxicity : Category 1B

Specific target organ toxicity

- repeated exposure

Category 1 (Bone marrow, Liver, Adrenal gland, spleen, Ovary)

GHS label elements

Hazard pictograms



Signal Word : Danger

Hazard Statements : H360Fd May damage fertility. Suspected of damaging the un-

born child.

H372 Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe mist or vapors. P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/ protective clothing/ eye protection/

face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:



Ganirelix Formulation



Date of last issue: 20.03.2023 Version Revision Date: SDS Number: 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste dis-

posal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)	
Ganirelix	124904-93-4	>= 0.01 -< 0.1	

SECTION 4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water. May damage fertility. Suspected of damaging the unborn

Most important symptoms

and effects, both acute and

child.

Causes damage to organs through prolonged or repeated

exposure.

First Aid responders should pay attention to self-protection, Protection of first-aiders

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

delayed

None known.





Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

Specific hazards during fire

fighting

Hazardous combustion prod-

ucts

: Exposure to combustion products may be a hazard to health.

No hazardous combustion products are known

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust

ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety





Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.

Store locked up. Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ganirelix	124904-93-4	TWA	0.2 μg/m3 (OEB 5)	Internal
		Wipe limit	2 μg/100 cm ²	Internal

Engineering measures : Use closed processing systems or containment technologies

to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

No open handling permitted.

Totally enclosed processes and materials transport systems

are required.

Operations require the use of appropriate containment technology designed to prevent leakage of compounds into

the workplace.

Personal protective equipment

Respiratory protection : No personal respiratory protective equipment normally

required.





Ganirelix Formulation

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : 5

Melting point/freezing point : No data available

Initial boiling point and boiling

range

100 °C

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : 23 hPa (20 °C)

Relative vapor density : No data available

Relative density : 1



Ganirelix Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

Solubility(ies)

Water solubility : completely miscible

Partition coefficient: n-

octanol/water

: No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac- :

tions

Can react with strong oxidizing agents.

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Ganirelix:

Acute toxicity (other routes of : LD50 (Rat): 40 mg/kg

administration)

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Public

Ganirelix Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

Components:

Ganirelix:

Species : Rabbit

Result : Mild eye irritation Method : Draize Test

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Ganirelix:

Test Type : Maximization Test

Species : Guinea pig
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Ganirelix:

Genotoxicity in vitro : Test Type: reverse mutation assay

Test system: Salmonella typhimurium

Result: negative

Test Type: reverse mutation assay Test system: Escherichia coli

Result: negative

Test Type: in vitro test

Test system: Chinese hamster ovary cells

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse

Application Route: Intravenous

Result: negative

Germ cell mutagenicity -

Assessment

•

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

May damage fertility. Suspected of damaging the unborn child.

Ganirelix Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

Components:

Ganirelix:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Subcutaneous
Duration of Single Treatment: 13 Weeks

Fertility: LOAEL: 0.1 µg/kg Result: Effects on fertility.

Test Type: Fertility/early embryonic development

Species: Rat, female

Application Route: Subcutaneous Duration of Single Treatment: 8 Weeks

Fertility: LOAEL: 10 µg/kg

Result: No effects on mating performance., Effects on fertility.

Test Type: Fertility Species: Monkey

Application Route: Subcutaneous

Fertility: NOAEL: 0.02 mg/kg body weight

Result: Effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat, female

Application Route: Subcutaneous Embryo-fetal toxicity.: LOAEL: 10 μg/kg

Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development

Species: Rabbit, female

Application Route: Subcutaneous Embryo-fetal toxicity.: LOAEL: 30 μg/kg

Result: Embryo-fetal toxicity.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of

adverse effects on development, based on animal

experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Bone marrow, Liver, Adrenal gland, spleen, Ovary) through prolonged or repeated exposure.

Components:

Ganirelix:

Routes of exposure : Ingestion

Target Organs : Bone marrow, Liver, Adrenal gland, spleen, Ovary

Assessment : Causes damage to organs through prolonged or repeated

exposure.



Ganirelix Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

Repeated dose toxicity

Components:

Ganirelix:

Species : Rat

NOAEL : 0.02 mg/kg
LOAEL : 2 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months
Target Organs : Bone marrow

Species : Mouse, female
LOAEL : 0.3 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Months

Target Organs : Liver, Adrenal gland, spleen, Ovary

Species : Mouse, male
LOAEL : 3 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Months

Target Organs : Liver, Adrenal gland, spleen

Species : Monkey
NOAEL : 2.5 mg/kg
Application Route : Subcutaneous
Exposure time : 6 Months

Remarks : No significant adverse effects were reported

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Ganirelix:

Inhalation : Symptoms: The most common side effects are:, vaginal

bleeding, Headache, Abdominal pain, Nausea, ectopic preg-

nancy, miscarriage

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ganirelix:

Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available



Ganirelix Formulation

♣ ORGANON

Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

Persistence and degradability

No data available

Bioaccumulative potential

No data available

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills.

Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

Ganirelix Formulation



Version Revision Date: SDS Number: Date of last issue: 20.03.2023 6.8 26.09.2023 22215-00021 Date of first issue: 15.10.2014

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Revision Date : 26.09.2023 Date format : dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature: SDS - Safety Data Sheet: TCSI - Taiwan Chemical Substance Inventory: TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety
Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.



Ganirelix Formulation

VersionRevision Date:SDS Number:Date of last issue: 20.03.20236.826.09.202322215-00021Date of first issue: 15.10.2014

MX / Z8